Informe de Evaluación de Tecnología Sanitaria y metaanálisis: comparación entre las formas farmacéuticas de tacrolimus

Sanguine, Verónica; Chaves, Silvia; Balaciano, Giselle.
Rev. argent. salud publica ; 8(33): 35-40, Dic. 2017. tab
Artículo en Español | LILACS | ID: biblio-883187

Documentos relacionados

  1. Long-term, prolonged-release tacrolimus-based immunosuppression in de novo kidney transplant recipients: 5-year prospective follow-up of the ADHERE study patients.
  2. A first small step toward personalized immunosuppression.
  3. Intestinal Permeability in Patients Early after Kidney Transplantation Treated with Two Different Formulations of Once-Daily Tacrolimus.
  4. A rational approach to guide cost-effective de novo donor-specific antibody surveillance with tacrolimus immunosuppression.
  5. MeltDose Technology vs Once-Daily Prolonged Release Tacrolimus in De Novo Liver Transplant Recipients.
  6. A pilot study of immunosuppression resumption following BK viremia resolution.
  7. Outcomes with Tacrolimus-Based Immunosuppression After Kidney Transplantation from Standard- and Extended-Criteria Donors - A Post Hoc Analysis of the Prospective OSAKA Study.
  8. High Tacrolimus Intrapatient Variability and Subtherapeutic Immunosuppression are Associated With Adverse Kidney Transplant Outcomes.
  9. A Phase I/IIa study of autologous tolerogenic dendritic cells immunotherapy in kidney transplant recipients.
  10. Pre-emptive immunosuppression using tacrolimus monotherapy does not reduce the rate of early acute rejection in renal transplantation from live donors: a comparative cohort study.